Table 1 Basic characteristics of patients with acquired VEN-R AML in our cohort
Characteristics | Value |
|---|---|
Patients (N) | 9 |
Male/Female (N) | 5/4 |
Age (year) | 73 (68–78) |
De novo/Secondary (N) | 8/1 |
FAB: M0/M1/M4/M5 (N) | 2/1/3/3 |
Karyotype: normal/abnormal (N) | 4/5 |
Bone marrow blast at venetoclax initiation (%) | 62 (23–92) |
Molecular feature at venetoclax initiation (N) | |
AML1-ETO | 1 |
NPM1 mutation | 3 |
FLT3-ITD | 4 |
DNMT3A mutation | 4 |
TP53 mutation | 1 |
ASXL1 mutation | 2 |
RUNX1 mutation | 2 |
Bone marrow blast at venetoclax resistance (%) | 10.5 (6–74) |
Molecular feature at venetoclax resistance (N) | |
AML1-ETO | 1 |
NPM1 mutation | 2 |
FLT3-ITD | 3 |
DNMT3A mutation | 3 |
TP53 mutation | 2 |
ASXL1 mutation | 2 |
RUNX1 mutation | 1 |
Cycles from venetoclax initiation to resistance (N) | 3 (3–15) |